Abstract:Objective: To explore the feasibility and accuracy of 0-1 h high sensitivity cardiac troponin I (hs-cTnI) concentration and its changes in judging non-ST segment elevation myocardial infarction (NSTEMI), and to investigate the feasibility of a simplified process. Methods: Patients with acute chest pain and suspected NSTEMI who were admitted to the emergency department of Fuwai Hospital, the First Affiliated Hospital of Sun Yat-sen University and Nanjing First Hospital from January 2017 to September 2020 were selected. Hs-cTnI test was carried out for the selected patients at the time of visit (0 h) and 1 h after visit. According to the 0-1 h hs-cTnI diagnostic process and threshold standard recommended by European Society of Cardiology (ESC) guidelines in 2015, the laboratory adjudication was determined. Cardiologists who did not participate in the project design and did not know the results of hs-cTnI test performed the clinical judgment according to the routine diagnosis and treatment process of emergency department. Taking clinical judgment as the gold standard, the diagnostic efficacy of 0-1 h hs-cTnI concentration and its change recommended by the guidelines for judging NSTEMI in Chinese population was analyzed. The guide process was simplified. Under the condition of not considering the time of chest pain, the guideline threshold was used for test and judgement, and the diagnostic efficacy of the simplified process was evaluated. Results: A total of 1 534 patients were enrolled in the study, aged (62±12) years and 952 (62.1%) patients were male. Among them, 402 patients (26.2%) were clinically diagnosed as NSTEMI and 1 132 patients (73.8%) were diagnosed as non-NSTEMI. According to the diagnosis and determination process recommended by the guidelines, NSTEMI was excluded in 672 patients (42.8%), and 464 patients (30.2%) were diagnosed as NSTEMI. The consistency rate with clinical determination reached 92.4% (1 050/1 136), the sensitivity of excluding diagnosis was 99.5% (95%CI: 98.0%-99.9%), the negative predictive value was 99.7% (95%CI: 98.8%-99.9%), and the negative likelihood ratio was 0.008 (95%CI: 0.002-0.335). The diagnostic specificity was 92.6% (95%CI: 90.9%-94.0%), the positive predictive value was 81.9% (95%CI: 78.0%-85.2%), and the positive likelihood ratio was 12.739 (95%CI: 10.356-15.670). According to the simplified process, NSTEMI was excluded in 675 patients (44.0%), and 463 patients (30.2%) were diagnosed as NSTEMI. The consistency rate with clinical judgment was 92.4% (1 051/1 138), the sensitivity of exclusion diagnosis was 99.3% (95%CI: 97.6%-99.8%), the negative predictive value was 99.6% (95%CI: 98.6%-99.9%), and the negative likelihood ratio was 0.012 (95%CI: 0.004-0.389). The diagnostic specificity was 92.6% (95%CI: 90.9%-94.0%), the positive predictive value was 81.9% (95%CI: 78.0%-85.2%), and the positive likelihood ratio was 12.705 (95%CI: 10.328-15.630). There was no significant difference in diagnostic efficacy between the simplified process and the recommended process (all P>0.05). Conclusion: The diagnostic process for judging NSTEMI according to the 0-1 h hs-cTnI concentration and its change criteria recommended by the 2015 ESC guidelines is applicable in the Chinese population and remains highly accurate in judging NSTEMI without considering the duration of chest pain at the time of presentation.

Machine Learning Diagnostic Model for Early Stage NSTEMI: Using hs-cTnI 1/2h Changes and Multiple Cardiovascular Biomarkers

[Efficacy Analysis of High-Sensitivity Troponin I Concentration and Its Changes in the Diagnosis of Acute Myocardial Infarction].

High-sensitivity cardiac troponin T for early prediction of non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome

Clinical application of high-sensitivity cardiac troponin T assay in the diagnosis of acute myocardial infarction

The Predictive Role of Cardiac Troponin Elevation Ratio Combined With Heart Function Index Model in the Prognosis of Non-ST-Segment Elevation Myocardial Infarction Patients

Evaluation Of The 0 H/1 H High-Sensitivity Cardiac Troponin T Algorithm In Diagnosis Of Non-St-Segment Elevation Myocardial Infarction (Nstemi) In Han Population

Serial troponin sampling over 60-minutes allows early distinction between myocardial infarction and chronic myocardial injury in patients presenting to emergency departments

Evaluation of clinical performance of cardiac troponin Ⅰ in diagnosis and prognosis of non-ST elevation acute coronary syndromes

Performance of high-sensitivity cardiac troponin T versus I for the early diagnosis of myocardial infarction

Machine learning for early prediction of acute myocardial infarction or death in acute chest pain patients using electrocardiogram and blood tests at presentation

Clinical Value of High Sensitivity Cardiac Troponin T in the Diagnosis of Acute Myocardial Infarction

Machine learning for diagnosis of myocardial infarction using cardiac troponin concentrations

Acute Changes In Hs-Ctni In An Exercise Test Setting: A Clinical Tool For Risk Stratification In Exercise-Based Cardiac Rehabilitation

Performance evaluation of a novel high-sensitivity cardiac troponin T assay: analytical and clinical perspectives

The Combination of Creatine Kinase-Myocardial Band Isoenzyme and Point-of-care Cardiac Troponin/contemporary Cardiac Troponin for the Early Diagnosis of Acute Myocardial Infarction

Application of Enhanced Cardiac Troponin Ⅰ Determination in Clinical Diagnosis of Acute Coronary Syndrome

Machine learning-based mRNA signature in early acute myocardial infarction patients: the perspective toward immunological, predictive, and personalized

Three-Biomarker Joint Strategy for Early and Accurate Diagnosis of Acute Myocardial Infarction Via a Multiplex Electrochemiluminescence Immunoarray Coupled with Robust Machine Learning

A multicenter prospective study on the ESC algorithm for the early diagnosis of non-ST-elevation myocardial infarction

Saturday, 31 August 2013

Development and validation of nomogram models to discriminate between acute aortic syndromes and non-ST-elevation myocardial infarction during troponin-blind period